Compare Ascendis Pharma A/S (ASND) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Jumia Technologies AG - ADR — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Jumia Technologies AG - ADR trades at $6.94 (market cap $868.21M). The key difference: Ascendis Pharma A/S is far larger — about 20.4× Jumia Technologies AG - ADR's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| ASND | JMIA | |
|---|---|---|
Market Cap | $17.74B | $868.21M |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $14.60 |
52-Week Low | $163.32 | $4.26 |
Enterprise Value | $18.11B | $815.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
JMIA trades at $7.01, up 1.45% today, amid a bearish technical signal and mixed earnings. The company reported Q1 2026 revenue growth of 39% but missed EPS expectations, with a net income margin of -30.79%. Cash flow improved with a net inflow of $21.31M in 2025, and management reaffirmed a 2027 profitability target. The stock shows neutral oscillators but bearish moving averages, with support and resistance clustered around $7.
The outlook hinges on JMIA's path to profitability by 2027, supported by expansion initiatives and partnerships like Starlink. Risks include persistent losses, competitive pressures in African e-commerce, and macroeconomic headwinds. Analyst consensus is strongly bullish with 71% buy ratings, but investors must weigh growth potential against execution risks and current negative returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
